Adding chiglitazar to your current diabetes medicine
Part of Hormones & metabolism clinical trials.
This study tests whether a new pill, chiglitazar, can help lower blood sugar when added to your current diabetes medicine (an SGLT-2 inhibitor). It may be an option if your blood sugar is still not well controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have type 2 diabetes.
- You have been taking a stable dose of an SGLT-2 inhibitor (like empagliflozin or dapagliflozin) alone or with one other diabetes pill for at least one month.
- Your blood sugar (HbA1c) is 7.5% or higher despite this treatment.
- You are not currently using insulin.
- Your kidneys and liver are functioning well enough (no severe kidney or liver disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational combination tablet for diabetes. It looks at how food affects the drug and how the body handles it when taken multiple times.
This trial tests a new oral medication, Chiglitazar, for people who have both type 2 diabetes and a fatty liver condition called MASH (fatty liver with inflammation and scarring). It aims to see if the drug can help improve liver health and diabetes control.
This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.
This trial tests a new combination pill that includes three medications to lower blood sugar in people with type 2 diabetes. It aims to see if this combination is safe and effective for Chinese patients.
This study tests whether adding a diabetes pill called pioglitazone to your current treatment (which includes an SGLT2 inhibitor and insulin) can lower your HbA1c (average blood sugar) further and prevent a dangerous rise in blood ketones, a byproduct that can cause serious complications. If it works, this combination may help improve blood sugar control in people with type 1 diabetes.
This trial tests a new pill, chiglitazar, to see if it can improve liver health in people with cirrhosis related to fatty liver disease. It aims to stop the disease from getting worse and prevent complications, and may benefit people with type 2 diabetes or obesity.
Hear when a new T2DM (Type 2 Diabetes Mellitus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.